ClinicalTrials.gg
CompletedNCT07166770Updated Sep 11, 2026

Community-Led COVID-19 Testing Intervention to Address Mistrust

An interventional study of Community-led discussion in COVID-19 and Trust, sponsored by Old Dominion University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Old Dominion University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this adapted intervention study is to assess how community-led group discussions about health-related topics may alter beliefs and intentions regarding healthcare recommendations, such as COVID-19 testing and vaccination.

Read the detailed description

Eligible participants were randomized to intervention or control group. Intervention group participants met virtually with other community member participants in small discussion groups once a week for 75 minutes over the course of 14 weeks. The online discussion groups were led by peer mentor facilitators and supported by a research team member. Discussion topics included current events and other health related topics. Control group participants did not meet in weekly discussion groups. At approximately the 0 weeks, 14 weeks, and 18 weeks time points, all participants answered online surveys about health related topics. At the 14 weeks and 18 weeks time points, all participants were asked to self-administer a COVID-19 test that investigators provide.

02

Conditions studied

  • COVID-19
  • Trust

Keywords

  • community-led
  • COVID-19
  • trust
  • vaccine hesitancy
  • peer mentor
  • community advisory board
03

In context

COVID-19

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

This study's enrollment of 49 is below the median of 102 across 4,364 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Old Dominion University is the lead sponsor of 27 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Resident of one of the 9 housing authority agencies
  • Willing to participate in Zoom meetings and complete online assessments at baseline, 14-week, and 18-week timepoints
  • Ability to read, speak, and understand English

Exclusion criteria

Exclusion Criteria:

  • May not have participated in Study 1
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • No intervention
    Control

    non-intervention control (participants complete surveys only)

  • Experimental
    Intervention

    Participants engage in weekly community-led small group discussions about health-related topics and answer surveys at 0, 14, and 18 week time points

    Behavioral: Community-led discussion

Interventions

  • BehavioralCommunity-led discussion

    Participants engage in weekly community-led small group discussions about health related topics

06

What researchers measure

Primary outcomes

  1. Openness to COVID-19 Testing

    The COVID-19 Testing Openness Questionnaire is an 7-item self-report measure designed to assess participants' openness to getting tested for COVID-19. Each item is rated on a 5-point scale, from 1 "Strongly Disagree" to 5 "Strongly Agree," with the sum of scores ranging from 7 to 35. Higher scores indicate greater openness to COVID-19 testing.

    Time frame: 0 weeks, 14 weeks, 18 weeks

  2. COVID-19 Testing Efficacy

    The COVID-19 Testing Efficacy Scale is a 6-item self-report measure that will assess participants' perceived self- and response-efficacy related to COVID-19 testing. Each item is rated on a 5-point scale ranging from 1 "Strongly Disagree" to 5 "Strongly Agree," with the sum of scores ranging between 6 and 30. Higher scores indicate greater efficacy.

    Time frame: 0 weeks, 14 weeks, 18 weeks

  3. Trust in the Safety of the COVID-19 Vaccine

    Trust in the safety of the COVID-19 vaccine was measured with one item which assessed participants' trust in the safety of the COVID-19 vaccine. The item is rated on a 5-point Likert scale. Higher scores indicate greater trust.

    Time frame: 0 weeks, 14 weeks, 18 weeks

  4. Trust in Efficacy of the COVID-19 Vaccine

    Trust in the efficacy of the COVID-19 vaccine was measured with one item which assessed participants' perceptions of efficacy related to the COVID-19 vaccine, or trust that it works as intended. The item is rated on a 5-point Likert scale. Higher scores indicate greater trust.

    Time frame: 0 weeks, 14 weeks, 18 weeks

Secondary outcomes

  1. COVID-19 Vaccine Hesitancy

    Vaccine Hesitancy was assessed by an item that asked, "Overall, how hesitant about the COVID-19 vaccine would you consider yourself to be?." This question was adapted from the Parent Attitudes about Childhood Vaccines (PACV) survey. The item is scored on a 5-point Likert scale, ranging from "1 - not at all hesitant" to "5 = very hesitant" with higher scores indicating greater hesitancy.

    Time frame: 0 weeks, 14 weeks, 18 weeks

  2. Social Connectedness

    The Social Connectedness Scale Revised is a 20-item scale that measures a participant's feeling of connection with other people and their community. Each item is rated on a 6-point scale ranging from 1 "Strongly Disagree" to 6 "Strongly Agree," with the sum of scores ranging between 20 and 120. Higher scores indicate greater connectedness.

    Time frame: 0 weeks, 14 weeks, 18 weeks

  3. Health Literacy

    The Health Literacy Scale (HLS-14) for Adults is a 14-item scale adapted for use in the US that measures an individual's ability to understand, access, and apply health-related information. Each item is rated on a 5-point scale ranging from 1 "Strongly Disagree" to 5 "Strongly Agree," with the sum of scores ranging between 14 and 70. Higher scores indicate greater health literacy.

    Time frame: 0 weeks, 14 weeks, 18 weeks

07

Study locations

1 site
  • Macon & Joan Brock Virginia Health Institute at Old Dominion University
    Norfolk, Virginia 23507, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jan 2026, 6 months.

Of 1,338 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 1,476 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 10, 2025
StartActual
Jul 1, 2025
Primary completionActual
Jan 27, 2026
CompletionActual
Jan 27, 2026
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07166770
Lead sponsor
Old Dominion University
Responsible party
Kelli J. England (Professor, Old Dominion University) — Principal investigator
First posted
Sep 10, 2025
Start date
Jul 1, 2025
Primary completion
Jan 27, 2026
Completion
Jan 27, 2026
Last update
Sep 11, 2026

Study contacts

Kelli J England, PhD
principal investigator · Old Dominion University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion